Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 4,280 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Blood samples collected Clear all

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Lorlatinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin, Pharmacokinetics of Fluorouracil Bolus (5-FU)
Interventions: zolbetuximab, oxaliplatin, leucovorin, fluorouracil, Pembrolizumab, folinic acid, nivolumab, Docetaxel; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Santa Monica, California • Chicago, Illinois + 2 more

Conditions: COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 1,877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 928
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 589 more

Conditions: Hematologic Tests
Interventions: Capillary blood draw; Diagnostic Test
Lead sponsor: Abbott Point of Care; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Hershey, Pennsylvania • Milwauke, Wisconsin

Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Anti-CFH Monoclonal Antibody GT103, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Pembrolizumab; Biological · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
Interventions: iC9.GD2.CAR.IL-15 T Infusion; Biological
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Stroke, Acute
Interventions: BrainPulse Device; Device
Lead sponsor: Jan Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Arlington Heights, Illinois • Evanston, Illinois • Cincinnati, Ohio

Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions: High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Year to 18 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Pediatric Cancer, Neuroblastoma, Sarcoma, Wilms Tumor and Other Childhood Kidney Tumors, Childhood Soft Tissue Sarcoma, Childhood Bone Sarcoma, Childhood Malignant Intestinal Neoplasm, Childhood Malignant Liver Neoplasm, Childhood Malignant Lung Neoplasm, Childhood Malignant Ovarian Neoplasm, Childhood Malignant Pleural Neoplasm, Childhood Neuroblastic Tumor, Childhood Sarcoma
Interventions: Wearing Smartwatch, Patient Report Outcomes, Blood Draw, Clinical Data Review; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years to 25 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Gastrointestinal Cancer, Head and Neck Cancer, Breast Cancer, Chemotherapy Effect, 5-Fluorouracil Toxicity
Interventions: Arterial blood pressure, Skin microcirculatory blood flow, Brachial artery blood flow, Venous blood draw; Other
Lead sponsor: Kansas State University; Other
Eligibility: 21 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Breast Cancer, Triple-negative Breast Cancer
Interventions: Tempus assay, Advanced pathology 1, Advanced pathology 2; Other
Lead sponsor: Laura Kennedy; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer
Interventions: mammography; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 311
States / cities: Fairbanks, Alaska • Scottsdale, Arizona • Fort Smith, Arkansas + 222 more

Conditions: Lung Cancer
Interventions: Sputum sample, Pulmonary function tests, Computerized tomography (CT) scan of the chest, Buccal epithelium collection, Nasal brushings, Bronchoscopy, Bronchoalveolar lavage, Blood sample collection, Urine sample, Questionnaire-data collection; Procedure · Radiation · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 55 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Adenosine A2B Receptor Antagonist PBF-1129, Biospecimen Collection, Nivolumab; Drug · Procedure · Biological
Lead sponsor: Dwight Owen; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Lung Carcinoma
Interventions: Best Practice, Biospecimen Collection, Exercise Counseling, Exercise Intervention, Medical Device Usage and Evaluation, Physical Performance Testing, Questionnaire Administration, Telemedicine; Other · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Docetaxel, Gemcitabine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Questionnaire Administration, Sacituzumab Govitecan; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 163
States / cities: Phoenix, Arizona • Irvine, California • Orange, California + 127 more

Conditions: Intracranial Venous Blood, Brain Cancers, Liquid Biopsy, Evaluate the Safety
Interventions: blood sampling; Diagnostic Test
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Sclerosis
Interventions: Alemtuzumab, Alemtuzumab immunotherapy; Drug
Lead sponsor: Samuel Forrester Hunter, MD, PhD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Kidney Transplant Rejection
Interventions: Diagnostic Test: TruGraf® Testing; Diagnostic Test
Lead sponsor: Transplant Genomics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pediatric or Young Adult Cancer Survivors
Interventions: Family History Questionnaire (FHQ), Salvia sample, Blood sample; Genetic · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 1,068 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Craniopharyngioma, Child
Interventions: Tumor and Blood Specimens; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Days to 21 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Neurological Outcome, Cardiac Arrest, Out-Of-Hospital Cardiac Arrest, Brain Anoxia Ischemia, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Cardiac Arrest With Successful Resuscitation, Cardiac Arrest, Out-Of-Hospital, Brain Injuries
Interventions: blood draw; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy, Flotufolastat F-18, Lutetium Lu 177 PSMA-10.1, Positron Emission Tomography, Single Photon Emission Computed Tomography; Procedure · Radiation · Other + 1 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

NCI COVID-19 in Cancer Patients, NCCAPS Study

Clinical Evaluation of Precision for the Potassium and Ionized Calcium Tests in Capillary Specimens

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Pilot Study of Acute Stroke Using the Brainpulse™

TReatment for ImmUne Mediated PathopHysiology

Biomarkers of Resiliency In Childhood Cancer Surgery

Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy

Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment

Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole

Nashville Early Diagnosis Lung Cancer Project

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers

Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects

Molecular Biomarkers in Renal Transplantation Via TruGraf® Test

Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness

Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects

Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy

Out-of-hospital Cardiac Arrest (OHCA) Biomarkers

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer